Inclusion Criteria:  age 20 or over uncontrolled HbA1c (7~10%) with metformin and/or sulfonylurea Hepatic steatosis estimated by Fibroscan (CAP ≥258 dB/m)  MAFLD: presence of any conditions  Overweight or obese: BMI ≥23 kg/m2 (Asian)  Metabolic dysregulation: at least of two of following criteria  Waist circumference: ≥90/80 cm in men and women (Asian) Blood pressure ≥130/85 mmHg or drug treatment Plasma triglycerides ≥150 mg/dL or drug treatment Plasma HDL-cholesterol <40/50 mg/dL for men and women or drug treatment Prediabetes (i.e. fasting glucose levels 100 to 125 mg/dL or 2-hour post-load glucose levels 140 to 199 mg/dL or HbA1c 5.7% to 6.4% HOMA-insulin resistance score ≥2.5 Plasma high-sensitivity CRP >2 mg/L  Exclusion Criteria:  Significant alcohol consumption Other competing causes for hepatic steatosis: viral hepatitis, drug-induced hepatitis, autoimmune hepatitis, hemochromatosis, Wilson's disease, alpha1 anti-trypsin deficiency, Celiac disease, Overt hypothyroidism, other secondary causes Type 1 diabetes mellitus medication usage within 3 months: vitamin E, PUFA, UDCA, fish oil, SGLT2 inhibitors, GLP1-RAs, TZDs  Severe organ dysfunction  liver damage: AST/ALT >x5 UNL, albumin <3.2, platelet <60k, Child-Pugh-Turcotte stage B or C kidney damage: serum creatinine ≥2.0 mg/dL or eGFR <50 mL/min/1.72m2 Hepatocellular carcinoma, active tumor, or metastasis End-stage liver disease